Skip to NavigationSkip to content

Dolutegravir

ViiV Healthcare launches Phase III trial for combo HIV treatment

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) as a combination treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

The GEMINI 1 and 2 studies will directly compare the drug combination with Tivicay plus Gilead’s Truvada (tenofovir/emtricitabine). Truvada has been shown to be an effective form of PrEP and is well on its way to becoming a blockbuster for Gilead.

ViiV HIV drug boost

ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its HIV drug dolutegravir.

The product was submitted in December for the treatment of HIV in combination with other antiretrovirals in adults and adolescents.

The US regulator has set a target date of 17 August to decide on the drug’s future, with the speed of the process reflecting dolutegravir’s potential to offer significant improvement to existing products.

Shionogi and ViiV strike new HIV deal

Shionogi image

HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment.

ViiV Healthcare was established in 2009 as a joint venture between GlaxoSmithKline and Pfizer, with GSK holding an 85% stake and Pfizer taking a 15% share.

Now Shionogi will gain a 10% share in ViiV in exchange for handing over rights to the drug, integrase inhibitor dolutegravir and other early-stage drugs in the same class.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches